UCB to Acquire Zogenix for up to $1.9B
January 19, 2022
UCB (Euronext: UCB) has agreed to acquire Zogenix, Inc. (NASDAQ: ZGNX) in a cash tender offer valuing the deal at up to approximately US$1.9 billion, consisting of US$26.00 per share in cash plus a contingent value right of up to US$2.00 per share tied to regulatory milestones. The acquisition adds Zogenix's FINTEPLA (fenfluramine) — an approved treatment for seizures associated with Dravet syndrome and under review for Lennox-Gastaut syndrome — to UCB's neurology and rare disease portfolio and is expected to expand UCB's epilepsy pipeline and global commercial reach.
- Buyers
- UCB, Zinc Merger Sub, Inc.
- Targets
- Zogenix, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
UCB To Acquire Candid Therapeutics for Up to $2.2 Billion
May 3, 2026
Biotechnology
UCB, a global biopharmaceutical company, has signed a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion. The deal includes $2.0 billion in upfront payments and up to $200 million in potential milestone payments, and is expected to close by the end of Q2 or early Q3 2026, subject to antitrust clearance and customary conditions.
-
UCB to Acquire Neurona Therapeutics for up to $1.15 Billion to Advance Epilepsy Cell Therapy
April 21, 2026
Healthcare Services
UCB announced a definitive agreement to acquire Neurona Therapeutics in a deal valued at up to $1.15 billion, including $650 million upfront and up to $500 million in potential milestone payments. The acquisition is intended to strengthen UCB’s epilepsy portfolio and expand it into regenerative medicine via Neurona’s lead cell therapy, NRTX-1001.
-
Neurocrine Biosciences to Acquire Celeno Therapeutics
April 7, 2026
Healthcare Services
Neurocrine Biosciences entered into a definitive all-cash agreement to acquire Celeno Therapeutics for approximately $2.9 billion. The deal is structured as a tender offer and is expected to close within ~90 days, subject to Hart-Scott-Rodino antitrust clearance and a majority of Celeno shares being tendered.
-
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion
April 6, 2026
Healthcare Services
Neurocrine Biosciences entered into a definitive agreement to acquire Soleno Therapeutics in an all-cash transaction valued at approximately $2.9 billion. The deal adds Soleno’s first-in-class therapy VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome to Neurocrine’s commercial portfolio, and is expected to close within 90 days subject to customary conditions and regulatory approvals.
-
Harmony Biosciences Acquires Zynerba Pharmaceuticals
August 14, 2023
Pharmaceuticals
Harmony Biosciences Holdings, Inc. has signed a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. in a cash tender offer valued at $60 million at closing ($1.1059 per share) plus a non-tradeable contingent value right (CVR) with potential additional payments of up to $140 million, for total potential consideration of up to $200 million. The deal is expected to close in the fourth quarter of 2023, subject to customary closing conditions and tendering by at least a majority of Zynerba’s outstanding shares.
-
UCB Acquires Engage Therapeutics
June 5, 2020
Pharmaceuticals
Belgium-based biopharma UCB has acquired Summit, New Jersey-based Engage Therapeutics for an upfront cash payment of US$125 million plus up to US$145 million in milestone payments, gaining worldwide rights to Staccato Alprazolam. The acquisition adds a late-stage, drug-device rescue therapy candidate for epilepsy to UCB's neurology portfolio and includes updated license and supply agreements with Alexza Pharmaceuticals.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.